M3, Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/04/30 | ¥14.80 | ¥11.11 | -24.9% |
| 2026/02/04 | ¥21.83 | ¥27.95 | +28.0% |
| 2025/11/12 | ¥14.00 | ¥16.03 | +14.5% |
| 2025/08/05 | ¥16.26 | ¥17.44 | +7.3% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
14.8M | +1.01% | |
|
MFS SERIES TRUST X-MFS International Intrinsic Value Fund
|
11.5M | 0.00% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
9.5M | +1.08% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.0M | +0.02% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.0M | +2.53% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.0M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
3.6K | +1.52% |
Dividend History 1Years Growth
Updated 2026/08/16| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥22 | +4.8% |
| 2025 | ¥21 | 0.0% |
| 2024 | ¥21 | +10.5% |
| 2023 | ¥19 | +18.8% |
| 2022 | ¥16 | - |
Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥208,159M | ¥230,818M | ¥238,883M | ¥284,900M |
| Gross Profit | ¥123,268M | ¥135,186M | ¥140,531M | ¥154,364M |
| Operating Income | ¥66,222M | ¥70,511M | ¥63,024M | ¥60,299M |
| Pretax Income | ¥96,239M | ¥74,387M | ¥69,231M | ¥65,502M |
| Net Income | ¥63,845M | ¥49,028M | ¥45,271M | ¥40,484M |
| EPS | ¥93.98 | ¥72.17 | ¥66.63 | ¥59.60 |
| Operating Margin | 31.81% | 30.55% | 26.38% | 21.16% |
| Balance Sheet | ||||
| Total Assets | ¥345,981M | ¥400,645M | ¥490,780M | ¥581,741M |
| Total Equity | ¥257,840M | ¥302,630M | ¥351,915M | ¥378,436M |
| Total Liabilities | ¥88,141M | ¥98,015M | ¥138,865M | ¥203,305M |
| Cash | ¥104,253M | ¥118,319M | ¥149,661M | ¥134,933M |
| Interest-bearing Debt | - | ¥111M | ¥18,514M | ¥24,420M |
| Equity Ratio | 74.52% | 75.54% | 71.71% | 65.05% |
| D/E Ratio | 0.00 | 0.00 | 0.05 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥52,108M | ¥57,113M | ¥58,310M | ¥51,743M |
| Investing CF | -¥23,407M | -¥21,933M | -¥39,456M | -¥39,149M |
| Financing CF | -¥16,371M | -¥22,837M | ¥9,432M | -¥27,165M |
| Free CF | ¥48,891M | ¥51,759M | ¥50,729M | ¥42,752M |
| Efficiency | ||||
| ROE | 24.76% | 16.20% | 12.86% | 10.70% |
| ROA | 18.45% | 12.24% | 9.22% | 6.96% |
Latest IR Information
-
Announcement on the Finalization of the Issuance Details for U-Stock Options (Stock Options)
The total number of stock options is 1,028 units, the asset value at the time of exercise is 1,884 yen per share (1,884 yen per share), and the exercise conditions per share have been finalized.
Read more -
Q1 of Fiscal Year 2027 Financial Summary [IFRS] (Consolidated)
Consolidated revenue for Q1 FY2027 reached 90,105 million yen (YoY +4.5%), operating income 18,077 million yen (△8.6%), and net income attributable to owners of parent 10,579 million yen (△21.8%). Segment-wise, Medical Platform and International segments were solid, but profitability worsened...
Read more -
This document contains forward-looking statements such as outlooks, plans, and targets related to our group. These statements are based on information currently available and reflect judgments as of the time of preparation of this document.
This document explains the current status of our medical platform and our future growth strategy, including value creation through AI and data utilization, the DX strategy, and expansion plans through M&A/partnerships. Key points include DX initiatives for FY2026 and plans...
Read more -
Notification on Grant of U Stock Options (Stock Acquisition Rights)
Stock options granted to 293 employees and subsidiary directors in total. Aggregate count is approximately 10,256 rights, with exercise period from 2028-08-07 to 2036-08-06, and the amount calculated in accordance with the exercise price. Includes provisions for adjustments in case...
Read more -
Notice Regarding Acquisition of Treasury Stock
The acquisition target shares are common shares, the number of acquired shares is 0 shares, and the total acquisition value is 0 yen. The acquisition period is from July 1, 2026 to July 31, 2026, and the method of acquisition...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,179
Rating Score: 1.75 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
M3, Inc. provides medical-related services to physicians and other healthcare professionals through the internet. It operates m3.com, a members-only website for providing information, tools, and services for medical professionals; MR-kun which delivers the latest medical information for daily medical practice; QOL-kun, a marketing support service that provides selected information useful for doctors; m3.com CAREER, a physician recruitment and career change support site; and Yakucari, a job search website for pharmacists. The company also provides online lectures; clinical trial; research targeting domestic medical professionals; medical-related self-planned data and research reports; global health professional research; survey panel provision services; and m3.com opening and management services. In addition, it offers AskDoctors, where registered doctors answer questions about health and illness from the public; MDLinx for medical professionals in the United States; and Doctors.net.uk, a website that provides services for pharmaceutical companies; and drug information database. Further, the company is involved in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; Support for recruiting subjects necessary for clinical development and clinical research, and related tasks; provision of management support to medical institutions, as well as visiting nursing, day care, and home care support services; and operates podiatry and venous disease clinics, and hospice facilities. Additionally, it offers clinical and medico-political news and education for medical professionals. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.